{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:06:59Z","timestamp":1778810819590,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160148"],"award-info":[{"award-number":["82160148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03765-0","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T16:01:48Z","timestamp":1693670508000},"page":"103-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Device-assisted intravesical chemotherapy versus bacillus Calmette\u2013Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis"],"prefix":"10.1007","volume":"56","author":[{"given":"Chengyu","family":"You","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangliang","family":"Qing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-8164","authenticated-orcid":false,"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"issue":"1","key":"3765_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part B: prostate and bladder tumours. Eur Urol 70(1):106\u2013119. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.028","journal-title":"Eur Urol"},{"issue":"3","key":"3765_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"3765_CR3","doi-asserted-by":"publisher","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM, Group EG-UTC (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette\u2013Guerin, and bacillus Calmette\u2013Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57(5): 766\u2013773. https:\/\/doi.org\/10.1016\/j.eururo.2009.12.024","DOI":"10.1016\/j.eururo.2009.12.024"},{"issue":"1","key":"3765_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Roupret M, Shariat SF, Seisen T, Soukup V, Sylvester RJ (2022) European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"issue":"3","key":"3765_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol 198(3):552\u2013559. https:\/\/doi.org\/10.1016\/j.juro.2017.04.086","journal-title":"J Urol"},{"issue":"3","key":"3765_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S, clinicalguidelines@esmo.org EGCEa (2022) Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(3):244\u2013258. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012","journal-title":"Ann Oncol"},{"key":"3765_CR7","doi-asserted-by":"publisher","unstructured":"Ojea A, Nogueira JL, Solsona E, Flores N, Gomez JM, Molina JR, Chantada V, Camacho JE, Pineiro LM, Rodriguez RH, Isorna S, Blas M, Martinez-Pineiro JA, Madero R, Group C (2007) A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette\u2013Guerin (27\u00a0mg) versus very low-dose bacillus Calmette\u2013Guerin (13.5\u00a0mg) versus mitomycin C. Eur Urol 52(5): 1398\u20131406. https:\/\/doi.org\/10.1016\/j.eururo.2007.04.062","DOI":"10.1016\/j.eururo.2007.04.062"},{"issue":"1","key":"3765_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette\u2013Guerin. Eur Urol 69(1):60\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045","journal-title":"Eur Urol"},{"key":"3765_CR9","doi-asserted-by":"publisher","unstructured":"Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ, International Mitomycin CC (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93(8): 597\u2013604. https:\/\/doi.org\/10.1093\/jnci\/93.8.597","DOI":"10.1093\/jnci\/93.8.597"},{"key":"3765_CR10","doi-asserted-by":"publisher","unstructured":"You C, Li X, Du Y, Wang H, Zhang X, Wei T, Wang A (2021) Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis. PeerJ 9:e12248. https:\/\/doi.org\/10.7717\/peerj.12248","DOI":"10.7717\/peerj.12248"},{"key":"3765_CR11","doi-asserted-by":"publisher","unstructured":"Zhao H, Chan VW, Castellani D, Chan EO, Ong WLK, Peng Q, Moschini M, Krajewski W, Pradere B, Ng CF, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan WS, Kelly J, Shariat SF, Witjes JA, Teoh JY (2021) Intravesical chemohyperthermia vs. bacillus Calmette\u2013Guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis. Front Surg 8:775527. https:\/\/doi.org\/10.3389\/fsurg.2021.775527","DOI":"10.3389\/fsurg.2021.775527"},{"issue":"1","key":"3765_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","volume":"60","author":"RJ Lammers","year":"2011","unstructured":"Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, Colombo R (2011) The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol 60(1):81\u201393. https:\/\/doi.org\/10.1016\/j.eururo.2011.04.023","journal-title":"Eur Urol"},{"issue":"3","key":"3765_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00345-009-0389-x","volume":"27","author":"SM Di Stasi","year":"2009","unstructured":"Di Stasi SM, Riedl C (2009) Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol 27(3):325\u2013330. https:\/\/doi.org\/10.1007\/s00345-009-0389-x","journal-title":"World J Urol"},{"key":"3765_CR14","doi-asserted-by":"publisher","unstructured":"Jung JH, Gudeloglu A, Kiziloz H, Kuntz GM, Miller A, Konety BR, Dahm P (2017) Intravesical electromotive drug administration for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 9 (9):CD011864. https:\/\/doi.org\/10.1002\/14651858.CD011864.pub2","DOI":"10.1002\/14651858.CD011864.pub2"},{"issue":"4","key":"3765_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.urolonc.2022.09.016","volume":"41","author":"MT Melgarejo-Segura","year":"2023","unstructured":"Melgarejo-Segura MT, Morales-Martinez A, Yanez-Castillo Y, Arrabal-Polo MA, Gomez-Lechuga P, Pareja-Vilchez M, Jimenez-Moleon JJ, Martin MA (2023) A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer. Urol Oncol 41(4):166\u2013176. https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.016","journal-title":"Urol Oncol"},{"issue":"1","key":"3765_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/2090598X.2020.1816150","volume":"19","author":"R Carando","year":"2020","unstructured":"Carando R, Soldini E, Cotrufo S, Zazzara M, Ludovico GM (2020) Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate- and high-risk patients. Arab J Urol 19(1):71\u201377. https:\/\/doi.org\/10.1080\/2090598X.2020.1816150","journal-title":"Arab J Urol"},{"issue":"6","key":"3765_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","volume":"83","author":"WS Tan","year":"2023","unstructured":"Tan WS, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P, Lazarowicz H, Mishra V, Rane A, Davies M, Warburton H, Cooke P, Mostafid H, Wilby D, Mills R, Issa R, Kelly JD (2023) Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial. Eur Urol 83(6):497\u2013504. https:\/\/doi.org\/10.1016\/j.eururo.2022.08.003","journal-title":"Eur Urol"},{"issue":"6","key":"3765_CR18","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJ Arends","year":"2016","unstructured":"Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, Moskovitz B, van der Heijden AG, Witjes JA (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette\u2013Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 69(6):1046\u20131052. https:\/\/doi.org\/10.1016\/j.eururo.2016.01.006","journal-title":"Eur Urol"},{"key":"3765_CR19","doi-asserted-by":"publisher","unstructured":"F\u00e9lix G-R, Daniel AG-P, Alejandro G-D, Federico de la R-K, Alfredo R-A, Brant AI, Felipe V-A (2022) Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol 40(4):999\u20131004. https:\/\/doi.org\/10.1007\/s00345-022-03928-1","DOI":"10.1007\/s00345-022-03928-1"},{"issue":"1","key":"3765_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000520630","volume":"107","author":"M Zazzara","year":"2023","unstructured":"Zazzara M, Nazaraj A, Scarcia M, Cardo G, Carando R, Ludovico GM (2023) Electromotive drug administration of mitomycin C (EMDA\/MMC) versus intravesical immunotherapy with bacillus Calmette\u2013Gu\u00e9rin (BCG) in intermediate and high risk non muscle invasive bladder cancer. Urol Int 107(1):64\u201371. https:\/\/doi.org\/10.1159\/000520630","journal-title":"Urol Int"},{"key":"3765_CR21","doi-asserted-by":"publisher","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647. https:\/\/doi.org\/10.1136\/bmj.g7647","DOI":"10.1136\/bmj.g7647"},{"issue":"8","key":"3765_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O\u2019Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E, National Cancer Institute PROCSG (2015) Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1(8):1051\u20131059. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2639","journal-title":"JAMA Oncol"},{"issue":"5","key":"3765_CR23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/s0197-2456(99)00026-4","volume":"20","author":"HD Clark","year":"1999","unstructured":"Clark HD, Wells GA, Huet C, McAlister FA, Salmi LR, Fergusson D, Laupacis A (1999) Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 20(5):448\u2013452. https:\/\/doi.org\/10.1016\/s0197-2456(99)00026-4","journal-title":"Control Clin Trials"},{"key":"3765_CR24","unstructured":"Wells GA, Shea B, O'Connell D et al (2000) The Newcastle Ottawa 1 Scale(NOS) for assessing the quality of nonrandomized studies in metaanalyses. Available at http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"3765_CR25","doi-asserted-by":"publisher","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","DOI":"10.1136\/bmj.d5928"},{"key":"3765_CR26","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hrobjartsson A, Kirkham J, Juni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schunemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"3765_CR27","doi-asserted-by":"publisher","unstructured":"Arrabal Polo MA, Melgarejo Segura MT, Yanez Castillo Y, Morales Martinez A, Pareja Vilchez M, Arrabal Martin M (2023) Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study. J Cancer Res Clin Oncol 1\u20137. https:\/\/doi.org\/10.1007\/s00432-023-04688-0","DOI":"10.1007\/s00432-023-04688-0"},{"issue":"3","key":"3765_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","volume":"170","author":"SM Di Stasi","year":"2003","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, Vespasiani G (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170(3):777\u2013782. https:\/\/doi.org\/10.1097\/01.ju.0000080568.91703.18","journal-title":"J Urol"},{"issue":"5\u20136","key":"3765_CR29","doi-asserted-by":"publisher","first-page":"E278","DOI":"10.5489\/cuaj.2708","volume":"9","author":"RG Ekin","year":"2015","unstructured":"Ekin RG, Akarken I, Zorlu F, Tarhan H, Kucuk U, Yildirim Z, Divrik RT (2015) Intravesical bacillus Calmette\u2013Guerin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer. Can Urol Assoc J 9(5\u20136):E278-283. https:\/\/doi.org\/10.5489\/cuaj.2708","journal-title":"Can Urol Assoc J"},{"issue":"4","key":"3765_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.5173\/ceju.2021.0122","volume":"74","author":"F Kostyev","year":"2021","unstructured":"Kostyev F, Bondar O, Chystiakov R, Lysenko V, Stavnychyi O, Varbanets V (2021) The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer. Central Eur J Urol 74(4):496\u2013502. https:\/\/doi.org\/10.5173\/ceju.2021.0122","journal-title":"Central Eur J Urol"},{"issue":"1","key":"3765_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"WS Tan","year":"2019","unstructured":"Tan WS, Panchal A, Buckley L, Devall AJ, Loubiere LS, Pope AM, Feneley MR, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths TRL, Page T, Hodgson D, Datta SN, Billingham LJ, Kelly JD (2019) Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette\u2013Guerin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus Calmette\u2013Guerin therapy (HYMN): a phase III, open-label, randomised controlled trial. Eur Urol 75(1):63\u201371. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.005","journal-title":"Eur Urol"},{"key":"3765_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13931","author":"S Wang","year":"2023","unstructured":"Wang S, Yu Z, Du P, Cao Y, Yang X, Ma J, Tang X, Zhang Q, Yang Y (2023) Combination of hyperthermia and intravesical chemotherapy for the treatment of pT1 stage bladder cancer: a retrospectively clinical study. Asia Pac J Clin Oncol. https:\/\/doi.org\/10.1111\/ajco.13931","journal-title":"Asia Pac J Clin Oncol"},{"key":"3765_CR33","doi-asserted-by":"publisher","unstructured":"Yuvaraja BT, Santosh SW, Preetham D, Ashish A, Abhinav PP, Nevitha A, Abhijit R, Archan K, Naresh B (2021) Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with mitomycin-C and intravesical bacillus Calmette\u2013Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer. Urol Ann 13(4):424\u2013430. https:\/\/doi.org\/10.4103\/ua.Ua_139_20","DOI":"10.4103\/ua.Ua_139_20"},{"issue":"5","key":"3765_CR34","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntanola P, Gimeno A, Blas M, Martinez-Pineiro JA (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette\u2013Guerin: the CUETO scoring model. J Urol 182(5):2195\u20132203. https:\/\/doi.org\/10.1016\/j.juro.2009.07.016","journal-title":"J Urol"},{"key":"3765_CR35","doi-asserted-by":"publisher","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013465; discussion 475\u2013467. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031","DOI":"10.1016\/j.eururo.2005.12.031"},{"issue":"3","key":"3765_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000502663","volume":"103","author":"R Carando","year":"2019","unstructured":"Carando R, Zazzara M, Cotrufo S, Ludovico GM (2019) Intravesical treatment with electro-mediated administration of mitomycin C as prophylaxis for intermediate and high-risk nonmuscle-invasive bladder cancer: a retrospective multicenter study. Urol Int 103(3):285\u2013290. https:\/\/doi.org\/10.1159\/000502663","journal-title":"Urol Int"},{"key":"3765_CR37","doi-asserted-by":"publisher","first-page":"1101830","DOI":"10.3389\/fonc.2022.1101830","volume":"12","author":"C Wang","year":"2022","unstructured":"Wang C, Jin W, Ma X, Dong Z (2022) The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia. Front Oncol 12:1101830. https:\/\/doi.org\/10.3389\/fonc.2022.1101830","journal-title":"Front Oncol"},{"issue":"4","key":"3765_CR38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrurol.2014.52","volume":"11","author":"H Zargar","year":"2014","unstructured":"Zargar H, Aning J, Ischia J, So A, Black P (2014) Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol 11(4):220\u2013230. https:\/\/doi.org\/10.1038\/nrurol.2014.52","journal-title":"Nat Rev Urol"},{"issue":"12","key":"3765_CR39","first-page":"1149","volume":"24","author":"EN Rampersaud","year":"2010","unstructured":"Rampersaud EN, Vujaskovic Z, Inman BA (2010) Hyperthermia as a treatment for bladder cancer. Oncology (Williston Park) 24(12):1149\u20131155","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"3765_CR40","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/09553007114551421","volume":"20","author":"WC Dewey","year":"1971","unstructured":"Dewey WC, Westra A, Miller HH, Nagasawa H (1971) Heat-induced lethality and chromosomal damage in synchronized Chinese hamster cells treated with 5-bromodeoxyuridine. Int J Radiat Biol Relat Stud Phys Chem Med 20(6):505\u2013520. https:\/\/doi.org\/10.1080\/09553007114551421","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"issue":"3","key":"3765_CR41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0022-5347(01)63728-5","volume":"159","author":"R Colombo","year":"1998","unstructured":"Colombo R, Da Pozzo LF, Lev A, Salonia A, Rigatti P, Leib Z, Servadio C, Caldarera E, Pavone-Macaluso M (1998) Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol 159(3):783\u2013787","journal-title":"J Urol"},{"issue":"6","key":"3765_CR42","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.purol.2020.03.005","volume":"30","author":"R Carando","year":"2020","unstructured":"Carando R, Pradere B, Afferi L, Marra G, Aziz A, Roghmann F, Krajewski W, Di Bona C, Alvarez-Maestro M, Pagliarulo V, Xylinas E, Moschini M (2020) The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: a systematic review. Prog Urol 30(6):322\u2013331. https:\/\/doi.org\/10.1016\/j.purol.2020.03.005","journal-title":"Prog Urol"},{"issue":"21","key":"3765_CR43","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.1002\/cam4.3513","volume":"9","author":"JL Lu","year":"2020","unstructured":"Lu JL, Xia QD, Lu YH, Liu Z, Zhou P, Hu HL, Wang SG (2020) Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Cancer Med 9(21):7800\u20137809. https:\/\/doi.org\/10.1002\/cam4.3513","journal-title":"Cancer Med"},{"issue":"9","key":"3765_CR44","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.21873\/anticanres.14535","volume":"40","author":"S Yamamoto","year":"2020","unstructured":"Yamamoto S, Kageyama Y, Fujii Y, Aizawa T, Urakami S, Fukui I (2020) Randomized study of postoperative single intravesical instillation with pirarubicin and mitomycin C for low-risk bladder cancer. Anticancer Res 40(9):5295\u20135299. https:\/\/doi.org\/10.21873\/anticanres.14535","journal-title":"Anticancer Res"},{"issue":"2","key":"3765_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ucl.2013.01.001","volume":"40","author":"DC Johnson","year":"2013","unstructured":"Johnson DC, Pruthi RS, Woods ME (2013) Perioperative chemotherapy: when to use it, what to use, and why. Urol Clin North Am 40(2):183\u2013195. https:\/\/doi.org\/10.1016\/j.ucl.2013.01.001","journal-title":"Urol Clin North Am"},{"issue":"5","key":"3765_CR46","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10147-011-0314-3","volume":"17","author":"T Okamura","year":"2012","unstructured":"Okamura T, Akita H, Ando R, Ikegami Y, Naiki T, Kawai N, Tozawa K, Kohri K (2012) Single monthly bacillus Calmette\u2013Guerin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer. Int J Clin Oncol 17(5):477\u2013481. https:\/\/doi.org\/10.1007\/s10147-011-0314-3","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"3765_CR47","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M, European Association of U (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639\u2013653. https:\/\/doi.org\/10.1016\/j.eururo.2013.06.003","journal-title":"Eur Urol"},{"issue":"1","key":"3765_CR48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ng1061","volume":"33","author":"L Dyrskjot","year":"2003","unstructured":"Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33(1):90\u201396. https:\/\/doi.org\/10.1038\/ng1061","journal-title":"Nat Genet"},{"issue":"2","key":"3765_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00345-008-0350-4","volume":"27","author":"J Park","year":"2009","unstructured":"Park J, Song C, Hong JH, Park BH, Cho YM, Kim CS, Ahn H (2009) Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer. World J Urol 27(2):277\u2013283. https:\/\/doi.org\/10.1007\/s00345-008-0350-4","journal-title":"World J Urol"},{"key":"3765_CR50","doi-asserted-by":"publisher","unstructured":"Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM (2007) Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 4(9):e284. https:\/\/doi.org\/10.1371\/journal.pmed.0040284","DOI":"10.1371\/journal.pmed.0040284"},{"issue":"Suppl 1","key":"3765_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000475205","volume":"27","author":"AP van der Meijden","year":"1995","unstructured":"van der Meijden AP (1995) Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur Urol 27(Suppl 1):23\u201328. https:\/\/doi.org\/10.1159\/000475205","journal-title":"Eur Urol"},{"key":"3765_CR52","doi-asserted-by":"publisher","unstructured":"Gonzalez-Padilla DA, Gonzalez-Diaz A, Guerrero-Ramos F, Rodriguez-Serrano A, Garcia-Jarabo E, Corona-laPuerta M, Rodriguez-Antolin A, Villacampa-Auba F (2021) Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia. Urol Oncol 39(1):76e79\u201376e14. https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.003","DOI":"10.1016\/j.urolonc.2020.07.003"},{"issue":"4","key":"3765_CR53","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/21681805.2021.1938664","volume":"55","author":"JA Thomsen","year":"2021","unstructured":"Thomsen JA, Nielsen Dominiak H, Lindgren MS, Jensen JB (2021) Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients. Scand J Urol 55(4):281\u2013286. https:\/\/doi.org\/10.1080\/21681805.2021.1938664","journal-title":"Scand J Urol"},{"issue":"3","key":"3765_CR54","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1179\/1973947813Y.0000000126","volume":"26","author":"L Wei","year":"2014","unstructured":"Wei L, Li Q, Liang H, Jianbo L (2014) The quality of life in patients during intravesical treatment and correlation with local symptoms. J Chemother 26(3):165\u2013168. https:\/\/doi.org\/10.1179\/1973947813Y.0000000126","journal-title":"J Chemother"},{"issue":"11","key":"3765_CR55","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41585-018-0092-z","volume":"15","author":"WS Tan","year":"2018","unstructured":"Tan WS, Kelly JD (2018) Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol 15(11):667\u2013685. https:\/\/doi.org\/10.1038\/s41585-018-0092-z","journal-title":"Nat Rev Urol"},{"issue":"1","key":"3765_CR56","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","volume":"18","author":"M Racioppi","year":"2018","unstructured":"Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF (2018) ElectroMotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer 18(1):1224. https:\/\/doi.org\/10.1186\/s12885-018-5134-7","journal-title":"BMC Cancer"},{"key":"3765_CR57","doi-asserted-by":"publisher","unstructured":"Juvet T, Mari A, Lajkosz K, Wallis CJ, Kuk C, Erlich A, Krimus L, Fleshner NE, Kulkarni GS, Zlotta AR (2020) Sequential administration of bacillus Calmette\u2013Guerin (BCG) and electromotive drug administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. Urol Oncol 38(11):850e859\u2013850e815. https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.031","DOI":"10.1016\/j.urolonc.2020.06.031"},{"key":"3765_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.002","author":"I Sanz Gomez","year":"2023","unstructured":"Sanz Gomez I, Huguet J, Bravo A, Robalino J, Rodriguez Faba O, Territo A, Gaya JM, Palou J, Breda A (2023) Sequential treatment with bacillus Calmette\u2013Guerin (BCG) and mitomycin C administered with electromotive drug administration (EMDA) in patients with high-risk nonmuscle invasive bladder cancer after BCG failure. Clin Genitourin Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2023.03.002","journal-title":"Clin Genitourin Cancer"},{"key":"3765_CR59","doi-asserted-by":"publisher","unstructured":"Melgarejo Segura MT, Morales Martinez A, Yanez Castillo Y, Arrabal Polo MA, Gomez Lechuga P, Pareja Vilchez M, Arrabal Martin M (2023) Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer. Urol Oncol 41(2):109e101\u2013109e108. https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.019","DOI":"10.1016\/j.urolonc.2022.10.019"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03765-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03765-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03765-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:16:50Z","timestamp":1704817010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03765-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["3765"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03765-0","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,2]]},"assertion":[{"value":"9 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}